How Medicinal Cannabis Prescribing Is Regulated in Australia

Australian regulatory information.

This page explains the legal and regulatory machinery behind medicinal-cannabis prescribing. Regulatory access is not clinical approval, and nothing here guarantees a prescription, treatment outcome or product supply.

Patients often ask whether medicinal cannabis is ‘legal’ or whether a doctor is ‘authorised’ to prescribe it. Those questions are understandable, but the Australian framework is more specific. Regulation determines how a therapeutic good can be accessed and supplied; clinical judgement determines whether prescribing is appropriate for a particular patient.

Most medicinal-cannabis products used in Australia are not included in the Australian Register of Therapeutic Goods (ARTG). The TGA therefore provides access mechanisms for unapproved therapeutic goods. The main medicinal-cannabis pathways are the Special Access Scheme (SAS) and the Authorised Prescriber (AP) pathway. A small number of medicinal-cannabis products are included in the ARTG and follow the usual requirements that apply to registered medicines.

This page is intentionally about regulation and prescribing authority. It does not attempt to replace DocTel’s prescription-assessment page or the broader Medicanna telehealth service.

Most prescription medicines in Australia go through a formal evaluation process before the TGA includes them on the Australian Register of Therapeutic Goods (ARTG) — the same register used for medicines a pharmacist can dispense against an ordinary prescription without any extra regulatory step. Very few medicinal-cannabis products have been through that full evaluation and registration process to date, largely because the volume and consistency of large clinical trial evidence across cannabis products has lagged behind more established medicine classes.

Rather than leaving patients with no lawful access while that evidence base matures, Australia uses separate access mechanisms — chiefly the Special Access Scheme and the Authorised Prescriber pathway — that let a registered practitioner access an unapproved product for a specific patient, or a defined class of patients, under conditions set by the TGA. This is not a loophole and not a lesser form of legality; it is a deliberate, documented access route that exists precisely because the ordinary registration pathway does not yet fit most cannabis products.

The practical consequence for a patient is that ‘unapproved’ does not mean ‘illegitimate’ — but it does mean the product has not been evaluated by the TGA to the same standard as a fully registered medicine, which is exactly why the practitioner’s own clinical judgement carries extra weight in this context.

The Special Access Scheme provides pathways for registered health practitioners to access unapproved therapeutic goods for individual patients. The category and process depend on the patient’s circumstances, the practitioner type and whether the product fits an established pathway.

For medicinal cannabis, the TGA states that the SAS Category B application pathway is commonly used where another SAS category does not apply. Under this pathway, the prescriber applies to the TGA for approval to supply an unapproved medicinal-cannabis product to an individual patient.

From a patient perspective, SAS access is not a self-application process. The clinical practitioner is responsible for the relevant application or notification and for determining whether the treatment is appropriate. A patient cannot obtain TGA approval independently and then require a doctor to prescribe.

• The patient first needs a clinical assessment.
• The practitioner decides whether an unapproved medicinal-cannabis product is justified.
• The relevant SAS requirements are completed by the practitioner when that pathway applies.
• A lawful prescription and pharmacy supply process still remain necessary after regulatory access requirements are met.

The Authorised Prescriber pathway allows an eligible medical practitioner to prescribe specified unapproved therapeutic goods to a class of patients with a particular condition without seeking a separate SAS approval for every individual patient covered by the authorisation.

Authorised Prescriber status does not mean a doctor can prescribe indiscriminately. The practitioner must remain within the scope of the authorisation and professional obligations, assess each patient clinically and maintain the required records and reporting.

A worked example: a practitioner holding Authorised Prescriber status for a defined condition does not mean every patient who books a consultation with that practitioner should receive a medicinal-cannabis prescription. The authorisation describes what the practitioner is permitted to do within a defined class of patients — it does not describe an outcome that is owed to any individual patient who happens to consult them. Each patient still needs their own clinical assessment against the same standard that would apply under any other pathway.

For patients, the distinction between SAS and AP can be less important than it appears online. The key question is not which acronym is used; it is whether the practitioner has an appropriate lawful pathway and whether the proposed treatment is clinically justified.

This is the single most important distinction on this page, and it is worth stating plainly rather than burying it in a longer paragraph.

A ‘yes’ to the first question never automatically answers the second. Regulatory access describes what a practitioner is legally permitted to do; it says nothing about whether treatment is right for the patient in front of them. Confusing the two is one of the most common misunderstandings in how medicinal cannabis is discussed publicly, and it is why this page treats them as two separate questions throughout rather than folding one into the other.

A TGA pathway does not guarantee that medicinal cannabis is suitable for an individual patient, does not prove that an unapproved product will be effective, and does not remove the practitioner’s professional obligations. For the patient-safety implications beside these regulatory controls, see DocTel’s medicinal-cannabis safety and quality standards guide.

• Regulatory access is not a clinical endorsement.
• Authorisation is not automatic prescribing.
• A lawful prescription does not guarantee immediate pharmacy stock.

The TGA regulates therapeutic goods and access pathways. It does not replace the treating practitioner’s clinical judgement. Regulatory access to an unapproved product should not be interpreted as a TGA endorsement that the medicine will work for a particular person.

The TGA also notes that unapproved therapeutic goods accessed through SAS or AP have not been evaluated by the TGA in the same manner as ARTG-included products. That makes informed consent, clinical reasoning and monitoring particularly important.

Patients should therefore be wary of marketing that presents a regulatory pathway as proof of effectiveness or as a guarantee of prescribing. Those are separate questions. When informal terms such as ‘medical marijuana’ or ‘medical weed’ are used, DocTel’s terminology guide explains how that search language maps back to the same Australian framework.

A clinician prescribing medicinal cannabis remains subject to the same fundamental professional duties that apply to other areas of medical practice: adequate assessment, informed consent, appropriate documentation, consideration of alternatives, safe prescribing and follow-up.

The presence of a TGA pathway does not reduce the need to review other medicines, mental-health history, pregnancy status, substance-use risk, impairment risk or the possibility that another diagnosis or treatment should be considered first.

In practice, the doctor may decide not to prescribe, may request further records, may recommend face-to-face assessment, or may suggest another treatment pathway. Those outcomes are compatible with a properly regulated service — an Authorised Prescriber declining to prescribe for a particular patient is not a failure of the pathway, it is the pathway working as intended.

• Document the clinical rationale for treatment decisions.
• Consider clinically appropriate ARTG-listed options before accessing an unapproved good where relevant.
• Provide information about risks, uncertainty and monitoring.
• Prescribe within professional scope and any applicable state or territory requirements.

Australia has a national therapeutic-goods framework, but controlled-medicine and prescribing requirements can also involve state and territory law. The exact administrative requirements can depend on the medicine, the patient and the jurisdiction.

Conceptually, the two layers answer different questions. The federal TGA framework governs whether a product can lawfully be accessed and supplied at all — the SAS and AP pathways described above. State and territory law can separately govern how a controlled medicine is prescribed, recorded and monitored within that state, and can include additional practitioner obligations on top of the federal ones, not instead of them. A practitioner operating a telehealth service across Australia needs both layers to be satisfied for each patient, not just one.

That is one reason generic online claims such as ‘approved Australia-wide’ can be misleading. A telehealth service can operate nationally while individual prescribing decisions still need to comply with the rules that apply to the practitioner and patient in their specific state or territory.

Patients do not need to become regulatory experts. They do need a practitioner who understands the relevant framework and can explain the clinical pathway in plain language.

Regulatory access, prescribing and dispensing are connected but distinct. A TGA pathway may allow a practitioner to prescribe an unapproved therapeutic good, but the medicine still needs to be prescribed lawfully and dispensed through an appropriate pharmacy process.

Availability can vary by pharmacy, product category, stock and jurisdiction. A prescription does not create a guarantee that a particular product is immediately available. Patients should follow the pharmacy and practitioner instructions if a substitution, supply delay or clarification is required.

DocTel does not treat regulatory approval as a product reservation or an automatic dispensing outcome. For the detailed pharmacy and dispensing pathway itself, see DocTel’s prescription assessment page.

A legitimate telehealth pathway should make clear that the consultation is an assessment, not an automated approval process. The doctor should be able to decline prescribing, request more information or recommend another form of care.

The service should also distinguish clinical fees from medication and pharmacy costs. Patients comparing providers can use DocTel’s medical cannabis cost and clinic pricing guide to understand those cost components separately. The service should also explain that a prescription is only issued when appropriate and avoid presenting unapproved medicinal-cannabis products as ordinary consumer goods.

Patients who are unsure whether the pathway may be suitable can use DocTel’s Medicanna eligibility check before booking.

• Australian-registered practitioner involvement.
• Clinical history and current medicines reviewed.
• No guaranteed prescription or guaranteed product.
• Clear follow-up and safety expectations.
• Lawful pharmacy dispensing rather than direct consumer-product sales.

Medicinal cannabis has a lawful medical pathway in Australia, but the phrase ‘legal in Australia’ can hide several different questions. A product may be lawfully supplied only through a particular therapeutic-goods pathway. A practitioner must be entitled to prescribe within the applicable framework. A pharmacy must dispense lawfully. The patient must then use and possess the medicine in accordance with the prescription and the law.

Those layers are why a blanket statement such as ‘cannabis is legal’ is not a useful description of medicinal access. The lawful status of recreational possession, driving and prescribed therapeutic use are separate matters.

Patients should therefore rely on the instructions attached to their prescription and obtain jurisdiction-specific advice where driving, travel, workplace obligations or controlled-medicine rules are relevant. DocTel’s safety and standards guide covers the driving and impairment question from a patient-safety angle.

Regulated prescribing also creates documentation obligations. The practitioner needs a clinical record that supports the treatment decision, while particular access pathways can involve TGA notifications, applications or reporting. Authorised Prescribers also have reporting responsibilities attached to their authorisation.

This administrative layer is not visible to most patients, but it matters because it distinguishes a medical service from an unstructured product-sales model. Good documentation also supports continuity of care when another practitioner or pharmacist needs to understand what has been prescribed and why.

Patients can help by providing accurate information and by keeping their own prescription information, pharmacy labels and treatment instructions available for follow-up — incomplete histories or inconsistent information can delay a decision because the practitioner may need to verify facts before prescribing. This matters even more if a patient later changes pharmacy or treating practitioner, since accurate records help the new provider understand what has previously been prescribed and monitored.

If you are considering medicinal cannabis, DocTel Medicanna provides a telehealth assessment pathway. The consultation is a clinical assessment and does not guarantee a prescription or a particular medicine.